Long Acting rFactor lX: Completed Phase II/III enrollment

Biogen Idec said at its analyst day that it completed enrollment in the open-label, international, pivotal Phase II/III B-LONG trial evaluating a low- and high-dose regimen of IV rFIXFc in about 129 p...